Eur J Clin Microbiol Infect Dis. 2022 Jan;41(1):147-151. doi: 10.1007/s10096-021-04330-2. Epub 2021 Aug 25.

Penicillin versus anti-staphylococcal beta-lactams for penicillin-susceptible Staphylococcus aureus blood stream infections: a retrospective cohort study.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology

Gemma Reynolds, Simeon Crawford, Jose Cuenca, Niladri Ghosh, Peter Newton

PMID: 34432165 DOI: 10.1007/s10096-021-04330-2

Abstract

The objective of the study is to assess the efficacy and tolerability of penicillins compared to anti-staphylococcal beta-lactams for treatment of penicillin-susceptible Staphylococcus aureus bloodstream infections (PSSA BSI). A retrospective cohort study was conducted of 140 sequential PSSA BSI presenting to a local health district (90 cases included). Penicillin susceptibility was confirmed by disc diffusion, Vitek® and Nitrocefin beta-lactamase methods. Clinical information regarding comorbidities and infection complexity was recorded. Antibiotic choice, dosage and duration were reviewed. Outcomes were compared according to the definitive treatment with either penicillin or ASBLs. The primary outcome was 30-day mortality. Secondary outcomes included renal injury, microbiological relapse and treatment tolerability. Ninety patients met inclusion criteria and were included in subsequent analysis. Of PSSA BSI, 69% were community acquired. Eighty-two percent had complex PSSA infections. The average duration of bacteraemia was 2.8 days (SD = 1.8 days). Sixty-six patients received definitive penicillin treatment, with a mean of 3.5 days of empiric antibiotics prior to penicillin. Twenty-four patients received definitive ASBL treatment (11 cefazolin, 13 flucloxacillin). There was no difference in 30-day mortality between groups (p = 1). There was no difference in renal injury (p > 0.5), hospital length of stay (p = 0.59) or microbiological relapse within 1 year (p = 0.17). Penicillin treatment was well tolerated. Our data supports penicillin as a suitable and well-tolerated alternative to ASBL in managing complex PSSA BSI.

© 2021. Crown.

References

1. Resistance AGoA (2021) Sepsis outcome programs - 2019 report. In: Care ACoSaQiH, editor. Level 5, 255 Elizabeth Street, Sydney NSW 2000: Australian Commission on Safety and Quality in Health Care - PubMed
2. Butler-Laporte G, Lee TC, Cheng MP (2018) Increasing rates of penicillin sensitivity in Staphylococcus aureus. Antimicrob Agents Chemother 26;62(7):e00680–18. https://doi.org/10.1128/AAC.00680-18 - PubMed
3. Limited TG. Directed therapy for bloodstream infections, including sepsis and septic shock. 2019. In: eTG complete [digital] [Internet]. Melbourne. Available from: https://tg.org.au . - PubMed
4. Henderson A, Harris P, Hartel G, Paterson D, Turnidge J, Davis JS et al (2019) Benzylpenicillin versus flucloxacillin for penicillin-susceptible Staphylococcus aureus bloodstream infections from a large retrospective cohort study. Int J Antimicrob Agents 54(4):491–495 - PubMed
5. Nissen JL, Skov R, Knudsen JD, Østergaard C, Schønheyder HC, Frimodt-Møller N et al (2013) Effectiveness of penicillin, dicloxacillin and cefuroxime for penicillin-susceptible Staphylococcus aureus bacteraemia: a retrospective, propensity-score-adjusted case–control and cohort analysis. J Antimicrob Chemother 68(8):1894–1900 - PubMed
6. SM. Bell JNP, D. L. Rafferty, J. K. Allerton, P. M. James (2018) Antibiotic susceptibility testing by the CDS method. In: Department of Microbiology NHP, editor. NSW: NSW Health Pathology - PubMed
7. Levi TM, de Souza SP, de Magalhães JG, de Carvalho MS, Cunha ALB, Dantas JGAdO et al (2013) Comparison of the RIFLE, AKIN and KDIGO criteria to predict mortality in critically ill patients. Rev Bras Ter Intensiva 25(4):290–6 - PubMed
8. Turnidge JD, Kotsanas D, Munckhof W, Roberts S, Bennett CM, Nimmo GR et al (2009) Staphylococcus aureus bacteraemia: a major cause of mortality in Australia and New Zealand. Med J Aust 191(7):368–373 - PubMed
9. Tong SY, Davis JS, Eichenberger E, Holland TL, Fowler VG Jr (2015) Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management. Clin Microbiol Rev 28(3):603–661 - PubMed
10. Minejima E, Mai N, Bui N, Mert M, Mack WJ, She RC et al (2020) Defining the breakpoint duration of Staphylococcus aureus bacteremia predictive of poor outcomes. Clin Infect Dis 70(4):566–573 - PubMed
11. Sweeney DA, Kalil AC (2020) Be quick but don’t hurry: septic shock, Staphylococcus aureus bacteremia, and the timing of appropriate antibiotics. Critical Care Med 48(4):608–609.  https://doi.org/10.1097/CCM.0000000000004278 - PubMed
12. Davido B, Lawrence C, Dinh A, Bouchand F (2018) Back to the future with the use of penicillin in penicillin-susceptible Staphylococcus aureus (PSSA) bacteremia. Am J Med. 131(4):e155 - PubMed
13. Tong SYC, Campbell A, Bowen AC, Davis JS (2019) A survey of infectious diseases and microbiology clinicians in Australia and New Zealand about the management of Staphylococcus aureus bacteremia. Clin Infect Dis 69(10):1835–1836 - PubMed
14. Papanicolas LE, Bell JM, Bastian I (2014) Performance of phenotypic tests for detection of penicillinase in Staphylococcus aureus isolates from Australia. J Clin Microbiol 52(4):1136–1138 - PubMed
15. Rao SN, Rhodes NJ, Lee BJ, Scheetz MH, Hanson AP, Segreti J et al (2015) Treatment outcomes with cefazolin versus oxacillin for deep-seated methicillin-susceptible Staphylococcus aureus bloodstream infections. Antimicrob Agents Chemother 59(9):5232–5238 - PubMed

Publication Types

• Journal Article